Building AI as Scientific Infrastructure: Platform Strategies for Drug Discovery

The pharmaceutical industry is undergoing a fundamental transformation in how it approaches artificial intelligence. The era of isolated AI experiments, where individual teams deploy point solutions to address narrow problems, is giving way to a platform era in which AI is treated as core scientific infrastructure, comparable in strategic importance to laboratory automation, clinical data management systems, and manufacturing execution platforms.

This shift reflects a hard-won lesson: the organizations extracting the greatest value from AI in drug discovery and development are not those with the most sophisticated individual models but those that have built integrated platforms connecting data, compute, algorithms, and domain expertise into reusable infrastructure that accelerates work across the entire R&D pipeline. When Eli Lilly announces a partnership with NVIDIA to build an AI factory powered by Blackwell DGX SuperPOD systems, or when large biopharma companies invest hundreds of millions in centralized AI platforms, they are signaling that AI has crossed the threshold from experimental technology to essential infrastructure.

For IT leaders, chief digital officers, and R&D technology executives in pharmaceutical and biotech organizations, the question is no longer whether to invest in AI but how to architect AI infrastructure that delivers compounding returns across drug discovery, clinical development, manufacturing, and regulatory science. This article provides a strategic and technical framework for building AI as scientific infrastructure within pharmaceutical organizations.

The Platform Shift: From Point Solutions to Scientific Infrastructure

The distinction between AI point solutions and AI infrastructure is critical for understanding the current strategic landscape. A point solution addresses a single problem: predicting protein structure, optimizing a clinical trial design, or identifying adverse events in safety reports. An AI platform provides the shared data, compute, tooling, and governance that enable many such applications to be developed, deployed, and maintained efficiently.

McKinsey’s research on AI in biopharma has identified a clear correlation between platform maturity and AI impact. Organizations that have invested in shared AI infrastructure report two to five times the return on AI investment compared to organizations pursuing project-by-project approaches. The platform effect creates compounding returns because each new AI application built on the platform benefits from the data integration, compute infrastructure, governance frameworks, and organizational learning accumulated by previous applications.

The pharmaceutical industry’s unique characteristics make the platform approach particularly valuable:

• Long value chains: Drug development spans discovery, preclinical research, clinical trials, regulatory submission, manufacturing, and commercialization. AI insights generated in one stage (such as target identification) directly inform decisions in subsequent stages (such as clinical trial design). A platform that connects AI applications across these stages amplifies the value of each individual application.
• Data reuse potential: The data generated during drug development, including molecular structures, assay results, clinical outcomes, manufacturing process data, and real-world evidence, has value far beyond its original purpose. A platform that makes this data discoverable, accessible, and computationally usable enables AI applications that would be impossible if data remained siloed in the systems where it was originally captured.
• Regulatory learning: Validation approaches, documentation standards, and regulatory strategies developed for one AI application can be templated and reused for subsequent applications on the same platform, reducing the regulatory burden for each new deployment.

Architecture Principles for Pharma AI Platforms

Building an AI platform for pharmaceutical R&D requires architectural decisions that balance scientific flexibility with enterprise reliability. The following principles, drawn from organizations that have successfully built and scaled pharma AI infrastructure, provide a foundation for platform architecture decisions.

Modularity and Composability

The platform should be composed of loosely coupled, independently deployable components that can be assembled in different configurations to support diverse use cases. A target identification application may require molecular databases, knowledge graphs, and generative chemistry models, while a clinical trial optimization application may need patient databases, protocol analytics, and enrollment prediction models. Both should draw from shared platform services without requiring monolithic integration.

Multi-Modal Data Architecture

Pharmaceutical AI must work with extraordinarily diverse data types: small molecule structures, protein sequences, genomic data, imaging data (histopathology, medical imaging, microscopy), clinical time-series data, free-text documents (protocols, regulatory submissions, scientific literature), and manufacturing process data. The platform’s data architecture must accommodate this diversity without forcing all data into a single model or storage format.

Reproducibility and Provenance

Scientific credibility and regulatory compliance both demand that AI experiments and production predictions be reproducible. The platform must track the complete lineage of every prediction: the data used for training and inference, the model version, the hyperparameters, the compute environment, and the preprocessing steps. This provenance tracking is not optional; it is foundational to both scientific integrity and regulatory acceptability.

Scalable Compute with Cost Governance

AI workloads in drug discovery can range from lightweight inference tasks that run in seconds to large-scale molecular simulations and foundation model training runs that consume thousands of GPU-hours. The platform must provide elastic compute that scales to meet peak demands while implementing cost governance mechanisms that prevent uncontrolled spending. Cloud-native architectures with spot instance support, workload scheduling, and cost allocation by project and department are essential.

Security and Compliance by Design

Pharmaceutical AI platforms handle some of the most sensitive data in the enterprise: proprietary compound libraries, unpublished clinical data, manufacturing trade secrets, and patient-level health information. Security, access control, data classification, and compliance capabilities must be embedded in the platform architecture, not bolted on after deployment. This includes role-based access control, data encryption at rest and in transit, audit logging, and compliance with regulations including 21 CFR Part 11, HIPAA, GDPR, and ICH guidelines.

The Data Foundation: Building the Biomedical Knowledge Graph

The single most valuable component of a pharmaceutical AI platform is its data foundation. The organizations achieving the greatest impact from AI in drug discovery have invested in building comprehensive biomedical knowledge graphs that integrate diverse data sources into a connected, queryable representation of biological and chemical knowledge.

A pharmaceutical knowledge graph typically integrates the following data domains:

The knowledge graph approach provides several advantages over traditional data warehousing for AI applications. It naturally represents the relationships between entities (genes, proteins, diseases, compounds, pathways) that are essential for biological reasoning. It supports federated queries that traverse multiple data domains to answer complex scientific questions. And it provides a framework for integrating new data sources incrementally without restructuring existing data.

Building a comprehensive biomedical knowledge graph is a multi-year investment. Organizations typically begin with a core set of internal data sources and high-value public databases, then expand the graph incrementally as new use cases require additional data domains. The key architectural decision is ensuring that the graph infrastructure is extensible from the outset, avoiding the need for fundamental redesign as the scope expands.

Compute Infrastructure: From Cloud to AI Factories

The compute requirements for pharmaceutical AI have grown dramatically as the field has progressed from traditional machine learning to deep learning and, most recently, to large foundation models. Training a molecular generation model or a protein language model can require thousands of GPU-hours, and the inference workloads for high-throughput virtual screening or molecular dynamics simulation can be equally demanding.

The concept of the AI factory, exemplified by Eli Lilly’s partnership with NVIDIA to deploy Blackwell DGX SuperPOD infrastructure, represents the leading edge of pharmaceutical compute investment. These purpose-built AI computing environments provide the concentrated GPU power needed for the most demanding pharmaceutical AI workloads, including foundation model training, large-scale molecular simulation, and real-time inference at scale.

However, not every pharmaceutical organization needs or can justify an on-premises AI factory. The compute strategy should be tiered based on workload characteristics:

The compute strategy must also address the growing importance of inference costs. As AI moves from research to production, the cost of running models in real-time against production data becomes a significant operational expense. Model optimization techniques including quantization, distillation, and efficient serving architectures are essential for controlling inference costs at scale.

AI Applications Across the Discovery Pipeline

A well-architected AI platform enables applications across every stage of the drug discovery pipeline. Understanding the application landscape helps inform platform design decisions by clarifying the data, compute, and integration requirements that the platform must support.

Target Identification and Validation

AI-driven target identification leverages genomic, transcriptomic, and proteomic data to identify disease-associated targets with higher probability of therapeutic relevance. Network analysis of protein interaction maps, causal inference from genetic association studies, and multi-modal integration of -omics datasets enable identification of novel targets and prediction of target tractability. These applications require access to large-scale biological databases, graph computation capabilities, and integration with experimental validation workflows.

Molecular Design and Optimization

Generative AI models can design novel molecular structures with desired properties, dramatically expanding the chemical space explored during lead identification. These models, trained on vast compound libraries and structure-activity relationship data, can propose candidate molecules that optimize multiple objectives simultaneously: potency, selectivity, ADMET properties, and synthetic accessibility. The platform must support generative model training on proprietary compound data, high-throughput virtual screening, and integration with medicinal chemistry workflows for experimental validation.

Preclinical Development

AI applications in preclinical development include toxicity prediction, formulation optimization, pharmacokinetic modeling, and biomarker identification. These applications draw on diverse data sources including in vitro assay data, animal study results, historical development data, and published literature. The platform must support integration across these data sources and provide the modeling infrastructure for both traditional machine learning and deep learning approaches.

Clinical Trial Design and Execution

AI can transform clinical development by optimizing trial design, improving patient recruitment and retention, enhancing data monitoring, and accelerating endpoint analysis. McKinsey’s research suggests that AI-enabled clinical trial optimization could reduce development timelines by 12 to 18 months for new molecular entities. The platform must integrate clinical data management systems, electronic health records (for synthetic control arm generation), and real-world evidence sources.

AI in Clinical Development and Regulatory Science

Beyond discovery, AI platform infrastructure creates transformative opportunities in the later stages of drug development where regulatory expectations and data complexity are highest.

Regulatory Submission Automation

The preparation of regulatory submissions, including INDs, NDAs, BLAs, and MAAs, involves assembling and reviewing hundreds of thousands of pages of documentation. AI applications for regulatory writing assistance, cross-reference checking, consistency validation, and format compliance can reduce submission preparation time significantly. Natural language processing models trained on successful historical submissions can identify gaps, inconsistencies, and areas requiring additional data before regulatory review.

Pharmacovigilance and Safety Surveillance

AI-enabled pharmacovigilance represents one of the most mature applications of AI in pharmaceutical operations. Natural language processing for adverse event case processing, signal detection algorithms operating across global safety databases, and predictive models for identifying emerging safety concerns all benefit from platform infrastructure that provides standardized access to safety data, validated NLP pipelines, and continuous monitoring capabilities.

Real-World Evidence Generation

The growing regulatory acceptance of real-world evidence for supplemental indications, label expansions, and post-market commitments creates demand for AI infrastructure that can integrate and analyze diverse real-world data sources. Claims databases, electronic health records, patient registries, and digital health data must be harmonized and made computationally accessible for AI-driven analysis. The platform must address the particular data quality, privacy, and representativeness challenges associated with real-world data.

Agentic AI: The Next Frontier in Biopharma Automation

The emergence of agentic AI, autonomous AI systems capable of planning, executing, and adapting multi-step workflows with minimal human intervention, represents a significant evolution in pharmaceutical AI capabilities. BCG’s analysis of agentic AI in biopharma identifies this technology as having the potential to deliver step-change improvements in operational efficiency across R&D, manufacturing, and commercial functions.

Agentic AI differs from traditional AI applications in several important respects. Where a traditional AI model receives an input and produces a single output (a prediction, a classification, a recommendation), an agentic system can decompose complex objectives into sub-tasks, execute those tasks using available tools and data sources, evaluate intermediate results, and adapt its approach based on what it learns. In pharmaceutical contexts, this means AI systems that can conduct literature reviews, formulate hypotheses, design experiments, analyze results, and iterate, all with strategic human oversight rather than step-by-step human direction.

The platform implications of agentic AI are substantial. Agentic systems require robust tool integration (APIs to laboratory systems, databases, computational tools), secure execution environments, comprehensive audit trails of autonomous decision-making, and governance frameworks that define the boundaries within which autonomous operation is permitted. Organizations building AI platforms today should architect for agentic capabilities even if their current applications are more conventional, as the transition to agentic workflows is likely to accelerate over the next two to three years.

Integration Architecture: Connecting AI to R&D Workflows

The value of an AI platform is realized only when AI capabilities are integrated into the workflows where scientists, clinicians, and regulatory professionals make decisions. Integration architecture is the bridge between AI infrastructure and operational impact.

Pharmaceutical R&D environments present distinctive integration challenges. The technology landscape typically includes dozens of specialized systems, each serving a specific scientific or operational function:

• Electronic lab notebooks (ELNs) where scientists design and record experiments
• Laboratory information management systems (LIMS) that track samples and test results
• Clinical data management systems (CDMS) that capture and manage clinical trial data
• Regulatory information management systems (RIMS) that manage submission content and tracking
• Manufacturing execution systems (MES) that control and record production processes
• Quality management systems (QMS) that manage deviations, CAPAs, and change controls

The integration architecture must provide bidirectional data flow between the AI platform and these operational systems. AI applications need access to the data these systems generate (for training and inference), and the insights AI produces need to be delivered back to users within the context of these systems (for decision support). This requires a combination of API-based real-time integration, event-driven architectures for time-sensitive applications, and batch integration for large-scale data synchronization.

A microservices-based integration layer, often implemented as an API gateway with standardized service contracts, provides the flexibility to connect diverse systems while maintaining the loose coupling that allows individual components to evolve independently. This approach also facilitates the gradual migration from legacy systems to modern alternatives without disrupting the broader AI platform.

Regulatory Considerations for AI Infrastructure

The FDA has been actively developing frameworks for the use of AI in drug development, and the agency’s evolving position has significant implications for how pharmaceutical companies architect their AI infrastructure. The FDA’s proposed framework for AI model credibility in drug and biological product submissions establishes expectations for documentation, validation, and ongoing monitoring that must be supported by the platform architecture.

Key regulatory expectations that the AI platform must accommodate include:

• Model transparency and explainability: Regulatory submissions that include AI-generated evidence must be accompanied by documentation that explains how the model works, what data it was trained on, how it was validated, and what its limitations are. The platform must capture and make accessible the metadata needed to produce this documentation.
• Data quality and integrity: The FDA expects that data used to train and validate AI models meets appropriate quality standards, with documented provenance and quality controls. The platform’s data governance capabilities must demonstrate that training data is accurate, complete, and representative of the intended population or use case.
• Validation and performance monitoring: AI models used in regulatory contexts must be validated against appropriate benchmarks and monitored for performance degradation over time. The platform must support automated performance monitoring, drift detection, and triggered revalidation workflows.
• Change management: Model updates, retraining events, and changes to data pipelines must be managed through controlled processes with appropriate documentation. The platform’s MLOps capabilities must enforce change control procedures that meet GxP expectations.

The FDA has also signaled openness to AI-enabled approaches in drug development, including the use of AI for identifying biomarkers, optimizing clinical trial designs, generating real-world evidence, and supporting manufacturing process optimization. This regulatory posture creates opportunity for organizations that build their AI infrastructure with regulatory compliance embedded in the platform rather than addressed as an afterthought for individual applications.

Build vs. Buy: Platform Strategy Decisions

Pharmaceutical organizations face a fundamental strategic choice in how they approach AI platform construction. The build-versus-buy decision for AI infrastructure is not binary; it involves positioning the organization along a spectrum that ranges from fully custom-built platforms to fully outsourced AI-as-a-service arrangements.

Most pharmaceutical organizations will adopt a hybrid approach, building proprietary capabilities where they create competitive differentiation (such as domain-specific models trained on proprietary data) while leveraging commercial platforms and cloud services for commodity infrastructure. The key strategic decision is identifying which AI capabilities are sources of competitive advantage that justify custom investment and which are infrastructure commodities that are better sourced from specialized providers.

Implementation Roadmap for AI Infrastructure

Building AI as scientific infrastructure is a multi-year journey that must be sequenced to deliver incremental value while building toward a comprehensive platform vision. The following roadmap provides a phased approach that balances immediate impact with long-term capability development.

Phase 1: Foundation (Months 1–6)

Establish the architectural blueprint and build the foundational data layer. This includes conducting a comprehensive assessment of existing AI initiatives, data assets, and technology infrastructure; defining the target platform architecture and technology stack; implementing the core data lake or lakehouse infrastructure with initial data source integrations; establishing the AI governance framework including risk classification, validation approach, and organizational accountability; and deploying a shared model development environment that consolidates fragmented tooling into a standardized platform.

Phase 2: First Applications (Months 4–12)

Deploy the first two to three production AI applications on the platform, selected for their combination of business value and architectural representativeness. These initial applications serve as proof points for the platform approach and stress tests for the platform architecture. The applications should span at least two different data domains and organizational functions to validate the platform’s flexibility. During this phase, also implement MLOps pipelines for automated model deployment and monitoring, build the model registry and governance tooling, and begin constructing the biomedical knowledge graph with initial domain coverage.

Phase 3: Scale (Months 9–18)

Expand the platform to support a broader portfolio of AI applications. This includes extending the knowledge graph to additional data domains, onboarding additional use case teams onto the platform with self-service tooling and documentation, implementing advanced capabilities such as feature stores, automated retraining pipelines, and A/B testing infrastructure, scaling compute infrastructure based on demand patterns observed during earlier phases, and integrating AI outputs into operational systems (ELNs, LIMS, CDMS) through the integration architecture.

Phase 4: Transformation (Months 15–30)

Transition from AI as an augmentation layer to AI as a core component of R&D operations. This phase involves deploying AI-first workflows where AI capabilities are integral to the process design rather than added as enhancements to existing processes, implementing agentic AI capabilities for complex multi-step scientific workflows, establishing federated learning and collaboration infrastructure that enables AI development across organizational boundaries while protecting proprietary data, building advanced regulatory science capabilities that leverage the platform for submission-quality AI evidence generation, and measuring and communicating the platform’s cumulative impact on R&D productivity and speed.

The pharmaceutical industry’s transition from experimental AI to AI as scientific infrastructure represents one of the most significant technology transformations in the sector’s history. The organizations that build comprehensive, well-governed AI platforms will compound their advantages over time as each new application built on the platform delivers value more quickly and at lower cost than the last. Those that continue to treat AI as a collection of isolated projects will find themselves increasingly unable to compete with platform-enabled competitors in drug development speed, research productivity, and operational efficiency.

At Sakara Digital, we help pharmaceutical and biotech organizations design and implement AI platform strategies that align technology architecture with scientific and business objectives. From data foundation design and compute strategy through integration architecture and governance frameworks, our team brings the cross-disciplinary expertise needed to build AI as durable scientific infrastructure. If your organization is ready to move beyond point solutions and build the platform for sustained AI advantage, contact our team to begin the conversation.